表面抗原水平低的非活性慢性乙型肝炎病毒携带者短期Peginter

StephenW

Short-term Peginterferon-Induced High Functional Cure Rate in Inactive Chronic Hepatitis B Virus Carriers With Low Surface Antigen Levels
Qing-Lei Zeng, Zu-Jiang Yu, Jia Shang, Guang-Hua Xu, Chang-Yu Sun, Na Liu, Chun-Xia Li, Jun Lv, Yan-Min Liu, Hong-Xia Liang, Zhi-Qin Li, Ya-Jie Pan, Qiu-Yue Hu, Wei Li, Da-Wei Zhang, Fu-Sheng Wang
Author Notes
Open Forum Infectious Diseases, Volume 7, Issue 6, June 2020, ofaa208, https://doi.org/10.1093/ofid/ofaa208
Published:
03 June 2020
Article history

    pdfPDF
    Split View
    Cite
    Permissions Icon Permissions
    Share

Abstract
Background

None of the current guidelines recommend antiviral therapy for inactive hepatitis B virus (HBV) carriers (IHCs).
Methods

In this real-world, multicenter, nonrandomized study, 32 participants meeting the inclusion criteria were enrolled 1:1 for treatment with peginterferon α-2b or monitoring without treatment based on participant preference. The expected treatment duration was 48 weeks. The primary end point was hepatitis B surface antigen (HBsAg) loss. The HBV vaccine could be injected after HBsAg loss.
Results

All patients had HBsAg levels of <20 IU/mL. The mean baseline HBsAg levels were 6.6 IU/mL and 5.8 IU/mL in the treated and untreated groups, respectively. Fifteen (93.8%) participants achieved HBsAg loss, 5 obtained HBsAg seroconversion after undergoing a mean of 19.7 weeks of therapy in the treated group, and no one in the follow-up group achieved HBsAg loss during a mean follow-up time of 12.6 months (P < .0001). Generally, the therapy was well tolerated. Nine of 11 individuals who exhibited HBsAg loss benefited from receiving the HBV vaccine.
Conclusions

This study provides justification for further studies of short-course peginterferon α-2b for the functional cure of IHCs with low HBsAg levels. Additionally, HBV vaccine injection is beneficial after interferon-induced HBsAg loss.
functional cure, hepatitis B surface antigen loss, hepatitis B vaccine, inactive hepatitis B virus carrier, peginterferon α-2b
Topic:

    surface antigens follow-up hepatitis b surface antigens hepatitis b, chronic hepatitis b virus viruses hepatitis b vaccines peginterferon

Issue Section:
Major Article

StephenW

表面抗原水平低的非活性慢性乙型肝炎病毒携带者短期Peginterferon诱导的高功能治愈率
曾庆雷，余祖江，尚佳，徐光华，孙昌宇，刘娜，李春霞，吕俊，刘彦敏，梁红霞，李志琴，雅-潘洁，胡秋月，李伟，张大为，王福生
作者须知
开放论坛传染病，2020年6月，第7卷，第6期，ofaa208，https://doi.org/10.1093/ofid/ofaa208
发布时间：
2020年6月3日
文章历史

    PDF格式
    拆分视图
    引用
    权限图标权限
    分享

抽象
背景

当前的指南均未建议对非活动性乙型肝炎病毒（HBV）携带者（IHC）进行抗病毒治疗。
方法

在这个真实的，多中心，非随机的研究中，符合入选标准的32名参与者按1：1比例接受了聚乙二醇干扰素α-2b的治疗或根据参与者的喜好进行了无治疗的监测。预期的治疗时间为48周。主要终点是乙型肝炎表面抗原（HBsAg）的丢失。 HBsAg丢失后可注射HBV疫苗。
结果

所有患者的HBsAg水平均<20 IU / mL。治疗组和未治疗组的平均基线HBsAg水平分别为6.6 IU / mL和5.8 IU / mL。治疗组平均接受19.7周的治疗后有15名（93.8％）参与者达到了HBsAg丢失，治疗组中有5位获得了HBsAg血清转化，随访组中没有人在平均12.6个月的平均随访时间内达到HBsAg丢失（P <.0001）。通常，该疗法耐受良好。表现出HBsAg缺失的11个人中有9个人从接受HBV疫苗中受益。
结论

这项研究为进一步研究短程聚乙二醇干扰素α-2b治疗低HBsAg水平的IHC提供了依据。另外，在干扰素诱导的HBsAg丢失后注射HBV疫苗是有益的。
功能治愈，乙型肝炎表面抗原丢失，乙型肝炎疫苗，乙型肝炎病毒携带者灭活，聚乙二醇干扰素α-2b
话题：

    表面抗原随访乙型肝炎表面抗原乙型肝炎，慢性乙型肝炎病毒乙型肝炎疫苗聚乙二醇干扰素

发行部分：
主要文章

StephenW

https://academic.oup.com/ofid/article/7/6/ofaa208/5850992